Revolution Medicines' Pancreatic Cancer Drug Sees Record Sales

• Revolution Medicines' pancreatic cancer drug Rasonque generated $198 million in sales in five weeks.
• Over 5,000 patients have been treated with Rasonque since its U.S. approval.
• Rasonque is a groundbreaking pan-RAS inhibitor.
• The drug's commercial debut is considered one of the best in history.
• The company reported a strong start to the U.S. launch of Rasonque.